(NASDAQ: ILMN) Illumina's forecast annual revenue growth rate of 6.03% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Illumina's revenue in 2026 is $4,343,000,000.On average, 24 Wall Street analysts forecast ILMN's revenue for 2026 to be $707,315,400,000, with the lowest ILMN revenue forecast at $674,289,000,000, and the highest ILMN revenue forecast at $734,378,700,000. On average, 24 Wall Street analysts forecast ILMN's revenue for 2027 to be $746,152,000,000, with the lowest ILMN revenue forecast at $695,695,000,000, and the highest ILMN revenue forecast at $784,377,000,000.
In 2028, ILMN is forecast to generate $793,245,200,000 in revenue, with the lowest revenue forecast at $735,907,700,000 and the highest revenue forecast at $867,554,600,000.